Cardiff Oncology (CRDF) Q2 Loss Down 19%

Cardiff Oncology (NASDAQ:CRDF), a biotechnology company focused on developing therapies for cancer patients with high unmet needs, reported its second quarter 2025 earnings on July 29, 2025. The headline news was the completion of patient enrollment for its crucial Phase 2 clinical trial in RAS-mutated metastatic colorectal cancer, a major milestone for its lead drug candidate, onvansertib. The company reported a GAAP net loss per share of $(0.21) for Q2 2025, which was better than the expected $(0.19). It also reported $121 thousand in GAAP revenue for Q2 2025, slightly above the $110 thousand analyst estimate. Operating expenses grew to $14.9 million, reflecting ongoing investments in clinical trials and staff. Overall, the quarter showed steady research progress but highlighted persistent operating losses typical of a clinical-stage biotech company, with a healthy cash cushion supporting future development. Source: Analyst estimates for the quarter provided by FactSet. Cardiff Oncology operates as a clinical-stage biotechnology company developing precision cancer medicines. Its business centers on advancing novel therapies that target specific cancer-driving genetic mutations, aiming to bring new treatments to patients with few options.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool